Trifluoroacetic acid → {1-{1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile
反応式
[CH3:1][N:2]1[C:6]([S:7]([N:10]2[CH2:15][CH2:14][CH:13]([N:16]3[CH2:19][C:18]([CH2:42][C:43]#[N:44])([N:20]4[CH:24]=[C:23]([C:25]5[C:26]6[CH:33]=[CH:32][N:31](COCC[Si](C)(C)C)[C:27]=6[N:28]=[CH:29][N:30]=5)[CH:22]=[N:21]4)[CH2:17]3)[CH2:12][CH2:11]2)(=[O:9])=[O:8])=[CH:5][CH:4]=[N:3]1.FC(F)(F)C(O)=O>C(Cl)Cl>[CH3:1][N:2]1[C:6]([S:7]([N:10]2[CH2:11][CH2:12][CH:13]([N:16]3[CH2:19][C:18]([CH2:42][C:43]#[N:44])([N:20]4[CH:24]=[C:23]([C:25]5[C:26]6[CH:33]=[CH:32][NH:31][C:27]=6[N:28]=[CH:29][N:30]=5)[CH:22]=[N:21]4)[CH2:17]3)[CH2:14][CH2:15]2)(=[O:9])=[O:8])=[CH:5][CH:4]=[N:3]1参加物
4
実験手順
To a solution of {1-{1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]piperidin-4-yl}-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile (56 mg, 0.1 mmol) in methylene chloride (1.5 mL) was added trifluoroacetic acid (1.5 mL). The mixture was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was dissolved in 2 mL of a methanol solution containing 20% ethylenediamine. After being stirred at room temperature for 1 hour, the mixture was purified by HPLC (method B) to give 20 mg (64.5%) of {1-{1-[(1-methyl-1H-pyrazol-5-yl)sulfonyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. LC-MS: 507.2 (M+H)+. 1H NMR (300 MHz, DMSO-d6): δ 12.08 (brs, 1H), 8.72 (d, 1H), 8.62 (s, 1H), 8.34 (s, 1H), 7.55 (d, 2H), 6.99 (d, 1H), 6.75 (s, 1H), 3.95 (s, 3H), 3.62 (dd, 2H), 3.45 (dd, 2H), 3.40 (m, 2H), 3.25 (s, 2H), 3.19 (m, 1H), 2.75 (m, 2H), 1.70 (m, 2H), 1.25 (m, 2H).